Arthrosi Therapeutics, Inc. announced it raised $26 Million in an initial filing from an offering of $30 Million

Company

Location

About

Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout.